Repligen Corporation (RGEN) Shares Bought by Thrivent Financial For Lutherans
Thrivent Financial For Lutherans boosted its position in Repligen Corporation (NASDAQ:RGEN) by 4.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,850 shares of the biotechnology company’s stock after buying an additional 780 shares during the period. Thrivent Financial For Lutherans’ holdings in Repligen Corporation were worth $664,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Comerica Bank increased its position in shares of Repligen Corporation by 5.7% in the fourth quarter. Comerica Bank now owns 35,963 shares of the biotechnology company’s stock worth $1,112,000 after buying an additional 1,951 shares during the last quarter. State Street Corp increased its position in Repligen Corporation by 12.3% in the fourth quarter. State Street Corp now owns 1,059,196 shares of the biotechnology company’s stock valued at $32,643,000 after buying an additional 116,068 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Repligen Corporation by 3.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 6,388 shares of the biotechnology company’s stock valued at $197,000 after buying an additional 223 shares in the last quarter. Putnam Investments LLC increased its position in Repligen Corporation by 1.1% in the fourth quarter. Putnam Investments LLC now owns 24,022 shares of the biotechnology company’s stock valued at $740,000 after buying an additional 254 shares in the last quarter. Finally, Norges Bank bought a new position in Repligen Corporation during the fourth quarter valued at about $8,527,000. Hedge funds and other institutional investors own 96.45% of the company’s stock.
Repligen Corporation (NASDAQ:RGEN) opened at 42.30 on Friday. Repligen Corporation has a 12 month low of $25.93 and a 12 month high of $46.81. The firm’s 50-day moving average is $39.63 and its 200 day moving average is $34.54. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of 111.61 and a beta of 1.32.
Repligen Corporation (NASDAQ:RGEN) last released its earnings results on Thursday, May 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.02. The business had revenue of $30.59 million for the quarter, compared to the consensus estimate of $29.28 million. Repligen Corporation had a net margin of 11.93% and a return on equity of 9.57%. The firm’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same period last year, the firm posted $0.12 earnings per share. Equities analysts predict that Repligen Corporation will post $0.55 earnings per share for the current year.
Several research firms have issued reports on RGEN. Zacks Investment Research downgraded shares of Repligen Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Jefferies Group LLC restated a “hold” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Repligen Corporation in a research note on Wednesday, June 28th. BidaskClub downgraded shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 14th. First Analysis restated an “equal weight” rating and issued a $40.00 price objective on shares of Repligen Corporation in a research note on Friday, April 21st. Finally, Janney Montgomery Scott upped their price objective on shares of Repligen Corporation from $42.00 to $47.00 in a research note on Friday, June 23rd. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $41.20.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.